1. Home
  2. FPI vs ADCT Comparison

FPI vs ADCT Comparison

Compare FPI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Farmland Partners Inc.

FPI

Farmland Partners Inc.

HOLD

Current Price

$11.59

Market Cap

541.2M

Sector

Real Estate

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$4.13

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FPI
ADCT
Founded
2013
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
541.2M
484.4M
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
FPI
ADCT
Price
$11.59
$4.13
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
749.6K
903.2K
Earning Date
05-20-2026
05-25-2026
Dividend Yield
3.01%
N/A
EPS Growth
N/A
30.86
EPS
0.61
N/A
Revenue
$52,178,000.00
$81,357,000.00
Revenue This Year
N/A
$1.15
Revenue Next Year
$10.62
$86.93
P/E Ratio
$19.62
N/A
Revenue Growth
N/A
14.85
52 Week Low
$9.37
$1.05
52 Week High
$13.23
$4.98

Technical Indicators

Market Signals
Indicator
FPI
ADCT
Relative Strength Index (RSI) 39.66 48.68
Support Level $11.22 $3.79
Resistance Level $11.70 $4.63
Average True Range (ATR) 0.36 0.31
MACD -0.17 0.00
Stochastic Oscillator 0.30 17.79

Price Performance

Historical Comparison
FPI
ADCT

About FPI Farmland Partners Inc.

Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: